Immunogenicity and safety of a rabies-based highly pathogenic influenza A virus H5 vaccine in cattle

Nir Paran, Christoph Wirblich, Catherine Olal, Alessandro Tarquinio, Kimberly H. Lohmeyer, Drishya Kurup, Stacey Schultz-Cherry, Ismaila Shittu, Gregory C. Gray, Dennis A. Bente, Pia U. Olafson, Matthias J. Schnell

Research output: Contribution to journalArticlepeer-review

Abstract

The circulation of highly pathogenic H5 influenza A viruses in cattle, other mammals, and wildlife threatens animal and human health. To address this, we vaccinated heifer-calves with a deactivated rabies-virus-based H5 vaccine, which was well-tolerated and elicited neutralizing antibodies against both clade-1 and clade-2.3.4.4b H5N1 viruses, comparable to naturally H5-infected and convalescing cows. The immune responses to the vaccine platform were durable for at least 200 days and unaffected by preexisting RABV immunity.

Original languageEnglish (US)
Article number197
Journalnpj Vaccines
Volume10
Issue number1
DOIs
StatePublished - Dec 2025

ASJC Scopus subject areas

  • Immunology
  • Pharmacology
  • Infectious Diseases
  • Pharmacology (medical)

Fingerprint

Dive into the research topics of 'Immunogenicity and safety of a rabies-based highly pathogenic influenza A virus H5 vaccine in cattle'. Together they form a unique fingerprint.

Cite this